118 related articles for article (PubMed ID: 37536020)
1. The synergistic effect of IDH mutation and NDRG-2 dysregulation in the progression of WHO-grade 4 astrocytomas.
Kurdi M; Fadul MM; Alkhayyat S; Sabbagh AJ; Alsinani T; Alkhotani A; Mulla N; Mehboob R; Fathaddin AA; Bamaga A; Faizo E; Baeesa S
Pathol Res Pract; 2023 Aug; 248():154733. PubMed ID: 37536020
[TBL] [Abstract][Full Text] [Related]
2. The effect of p53 on the activity of NRF2 and NDRG2 genes through apoptotic pathway in IDH-wildtype glioblastoma.
Kurdi M; Baeesa S; Fadul MM; Alkhotani A; Alkhayyat S; Karami MM; Alsinani T; Katib Y; Fathaddin AA; Faizo E; Lary AI; Almansouri M; Maghrabi Y; Alyousef MA; Addass B
Pathol Res Pract; 2024 Feb; 254():155118. PubMed ID: 38241776
[TBL] [Abstract][Full Text] [Related]
3. Major Histocompatibility Class-I (MHC-I) downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure.
Butt NS; Kurdi M; Fadul MM; Hakamy S; Addas BMJ; Faizo E; Alkhayyat S; Bamaga AK; Alsinani T; Katib Y; Okal F; Maghrabi Y; Sabbagh AJ; Moshref R; Albalawi S; Alkhotani A; Mohammed F; Mulla N; Baeesa S
Pathol Res Pract; 2023 Oct; 250():154816. PubMed ID: 37725880
[TBL] [Abstract][Full Text] [Related]
4. The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Butt N; Enani M; Alshanqiti M; Alkhotani A; Alsinani T; Karami MM; Fadul MM; Almansouri M; Hassan A; Baeesa S; Bamaga AK; Alkhayyat S; Faizo E; Kurdi M
Folia Neuropathol; 2023; 61(3):317-325. PubMed ID: 37818692
[TBL] [Abstract][Full Text] [Related]
5. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
6. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
[TBL] [Abstract][Full Text] [Related]
7. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
8. The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment.
Kurdi M; Mulla N; Katib Y; Alsinani T; Hakamy S; Mj Addas B; Malibary H; Halawa TF; S Farhan M; Faizo E; Baeesa S
Biologics; 2023; 17():15-22. PubMed ID: 36778762
[TBL] [Abstract][Full Text] [Related]
9. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W
Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
11. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
12. IRX1 is a novel gene, overexpressed in high-grade IDH-mutant astrocytomas.
Sugur HS; Rao S; Sravya P; Athul Menon K; Arivazhagan A; Mehta B; Santosh V
Pathol Res Pract; 2023 May; 245():154464. PubMed ID: 37116364
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract][Full Text] [Related]
14. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
15. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ
J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737
[TBL] [Abstract][Full Text] [Related]
16. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
17. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of NDRG2 in human astrocytomas.
Li L; Wang J; Shen X; Wang L; Li X; Liu Y; Shi M; Zhao G; Deng Y
J Neurol Sci; 2011 Sep; 308(1-2):77-82. PubMed ID: 21705028
[TBL] [Abstract][Full Text] [Related]
19. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
[TBL] [Abstract][Full Text] [Related]
20. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]